Status: Recruiting
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma
Participants needed: 42
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: LTZ Therapeutics, Inc.Updated: Feb 10, 2026Locations: 5
Eligibility criteria
Age ≥ 18 years [+4]
CLL, or Richters transformation [+10]